ClinicalTrials.gg
RecruitingNCT06345937MsFITUpdated Sep 17, 2025

Multiple Risk Factor Intervention Trial (Ms. FIT)

An interventional study of Behavioural Experimental: guidelines-based physical activity and Behavioural Experimental: guidelines-based physical activity and healthy eating in Metabolic Disturbance and Sedentary Behavior, sponsored by University of Toronto. Recruiting at 1 site in Canada. Open to female participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by University of Toronto · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
30 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Sedentary Behavior with a site in Canada — 18 open to participants now, 19 under way, none of them phase 3. Sedentary Behavior · Canada.

Planned enrollment
15th of 69
180 · median 50
Started
2024
with 4 others
No phase
67 of 73
18 open now
Primary completion
2027-08
later than 14 of 18 live
Registered
61st of 73
by date
Lead sponsor
9 of 73
University of Toronto

Among the 73 studies in Sedentary Behavior with a site in Canada, this one is the 15th largest by planned enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2024, is one of 67 with no phase, reaches primary completion later than 14 of the 18 other live ones, and was the 61st registered.

Sedentary Behavior

1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.

Browse Sedentary Behavior studies →

Open to participants now

18 of the 73 studies in Sedentary Behavior with a site in Canada are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.

This study: 30 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Sedentary Behavior with a site in Canada, or all of them as a file.
02

Study summary

This study aims to produce new evidence, specific to women, on the efficacy and mechanisms of exercise and diet for cardiometabolic risk reduction in pre and postmenopausal women. Using a 3-arm randomized controlled trial (RCT) with equal recruitment and stratification by menopausal status to 6 months of: 1) exercise following Health Canada guidelines; 2) the same exercise plus counselling to follow Canada's Dietary Guidelines to improve diet quality; or 3) stretching group, this study will answer the following questions:

  • How does the impact of exercise compare among each of the causal links between physical inactivity and cardiometabolic disease in women?
  • What is the effect modification of adding a diet quality intervention to exercise?
  • What is the effect modification by menopausal status?

The investigators hypothesize that exercise adaptations will be: 1) largest peripherally, including Matsuda index (primary outcome), Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), arteriovenous oxygen difference (avO2diff), and visceral fat, compared to centrally (stroke volume (SV), endothelial function, aortic stiffness), 2) blunted or absent in post vs premenopause; 3) enhanced by the addition of diet quality which will be essential or additive for Matsuda index, metabolic syndrome, Framingham cardiovascular disease (CVD) risk, cytokines and adipokines, thigh myosteatosis, muscle mass, peak oxygen uptake (VO2peak), 4) enhanced by adding diet quality in more outcomes postmenopause.

03

Conditions studied

  • Metabolic Disturbance
  • Sedentary Behavior

Browse trials for

Keywords

  • Primary Prevention
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Biologically female
  • Aged 30+
  • Pre- or : Premenopause: having regular menstrual cycles (21-35 days long without a persistent difference of ≥7 days between cycles). Post-menopause: ≥12 months of amenorrhea or history of double oophorectomy and do not have irregular or occasional menstrual cycle in last 12 months.
  • Participants will have multiple risk factors for cardiometabolic disease, namely: being sedentary (\<30 min of moderate-vigorous physical activity/week), having a ≥ 25 kg/m\^2, and one or more of the following: a waist circumference indicative of abdominal obesity, specific to BMI (e.g., BMI 25-29.9: WC: ≥90cm; BMI 30-34.9: WC: ≥105cm; BMI 35-35.9: WC: ≥115cm) OR a diagnosis of either hypertension, pre-diabetes (heightened blood sugar levels), or dyslipidemia (heightened blood lipid levels)
  • Able to commit to come to the University once per week for 24 weeks.

Exclusion criteria

Exclusion Criteria:

  • Perimenopausal or those whom the investigators cannot discern pre- vs perimenopausal status
  • Diagnosed cardiovascular diseases, type 2 diabetes, non-alcoholic fatty liver disease, cancer (except for non-melanoma skin cancer), or respiratory disease (e.g., (COPD) or severe or uncontrolled asthma).
  • Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease (taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1: pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, loss of balance or passing out, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue with usual activities.)
  • American Heart Association's absolute or relative for symptom-limited maximal exercise testing (myocardial infarction, aortic or coronary artery stenosis, heart failure, pulmonary embolism or deep vein thrombosis, inflammation of the heart (myocarditis, pericarditis, and/or endocarditis), uncontrolled cardiac arrythmia, advanced or complete electrical heart block, stroke or transient ischemia attack, blood pressure >200mmHg/100mmHg, a cancer diagnosis other than skin cancer)
  • Unable to provide or communicate in English
  • Pregnant or breast-feeding currently or in the past 3 months
  • Mobility limitations to aerobic exercise (i.e., wheelchair, walker use, limp impeding walking)
  • Smoking cigarettes or marijuana within the past 3 months
  • Taking exogenous hormones in any format currently or in the past 3 months
  • Contraindications to research MRI (e.g., pacemaker, magnetic implants)
  • exceeding 40 kg/m2
  • Extreme claustrophobia
  • Self-report >30 min/week of moderate-to-vigorous intensity aerobic physical activity
  • Following a diet that largely restricts entire food groups or time of eating (e.g., vegan, ketogenic, carnivore, one meal a day) in last 3 months
  • Students in classes or labs of the professors who are involved in the study
  • Experienced significant weight loss (i.e., >5 kg) in past 3 months
  • Currently taking weight loss medications
  • Diagnosed history of an eating disorder or self-report of potential undiagnosed eating disorder
  • Plans to be away/unavailable for a substantial period of the intervention overall (i.e., >4 weeks throughout the 6 months or >2 weeks within the first 12 weeks of the intervention).
  • Allergies to local anesthetics
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Guidelines-based physical activity

    150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening

    Behavioral: Behavioural Experimental: guidelines-based physical activity

  • Experimental
    Guidelines-based physical activity and healthy eating

    150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening + counselling to follow Canada's Food Guide

    Behavioral: Behavioural Experimental: guidelines-based physical activity and healthy eating

  • Placebo comparator
    Stretching exercise

    Whole-body stretching

    Behavioral: Behavioural: Stretching exercise

Interventions

  • BehavioralBehavioural Experimental: guidelines-based physical activity

    Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.

  • BehavioralBehavioural Experimental: guidelines-based physical activity and healthy eating

    Behavioural Experimental: guidelines-based physical activity: Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening. Behavioural Experimental: guidelines-based healthy eating: One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.

  • BehavioralBehavioural: Stretching exercise

    Twice weekly virtual instructor-led whole-body stretching.

06

What researchers measure

Primary outcomes

  1. Insulin resistance

    As assessed by the Matsuda Index calculated from an oral glucose tolerance test (OGTT).

    Time frame: 6 months

Secondary outcomes

  1. Hepatic insulin resistance

    Indirectly measured via HOMA-IR using fasting glucose and insulin levels

    Time frame: 6 months

  2. Metabolic syndrome severity

    Calculated as a z-score to allow for tracking change in the interventions

    Time frame: 6 months

  3. Framingham 10-year risk (%)

    Calculated using a widely-used standardized scoring system

    Time frame: 6 months

Other outcomes

  1. Cardiorespiratory fitness

    Measured as peak volume of oxygen consumption via indirect calorimetry during a cardiopulmonary exercise test on a treadmill.

    Time frame: 6 months

  2. Heart Rate Recovery

    Measured as the difference between peak heart rate during the cardiorespiratory fitness test and heart rate 2-minutes after stopping the exercise test.

    Time frame: 6 months

  3. Exercise stroke volume & cardiac output

    Measured during submaximal and maximal periods of a cycling exercise test, using echocardiography.

    Time frame: 6 months

  4. Left ventricular ejection fraction

    Measured during rest, submaximal and maximal periods of cycling exercise test, using echocardiography

    Time frame: 6 months

  5. Left ventricular mass

    Measured via echocardiography at rest

    Time frame: 6 months

  6. Arteriovenous Oxygen Difference (avO2diff)

    Measured using two methods: (1) calculated as the volume of oxygen (VO2) from the corresponding workload from the day 1 treadmill test divided by cardiac output at rest, submaximal, and maximal periods of the cycling exercise test; and (2) direct assessment using near-infrared spectroscopy as a measure of tissue oxygenation in the legs at rest, submaximal, and maximal periods of the cycling exercise test.

    Time frame: 6 months

  7. Endothelial Function

    Measured using a brachial artery flow-mediated dilation test using ultrasound.

    Time frame: 6 months

  8. Carotid Intima Media Thickness

    Measured using a common carotid artery image using ultrasound.

    Time frame: 6 months

  9. Central & Peripheral Arterial stiffness

    Measured as the pulse wave velocity of the central (carotid-femoral) and peripheral leg (femoral-dorsalis pedis) and arm (carotid-radial) regions. Blood pressure may be added as covariate in analysis of arterial stiffness.

    Time frame: 6 months

  10. Blood Pressure

    Measured as the average of the last 5 of 6 blood pressure measurements using an automatic blood pressure device.

    Time frame: 6 months

  11. Resting Heart Rate & Heart Rate Variability

    Assessed using a 3-lead electrocardiogram in the supine position for 10 minutes after a 5-minute supine rest.

    Time frame: 6 months

  12. Thigh Myosteatosis

    Measured as thigh muscle fat fraction (percent of muscle compartment composed of fat pixels) determined from contiguous axial fat-water separation 3 Tesla (3T) magnetic resonance images of both thighs.

    Time frame: 6 months

  13. Knee flexion and extension (strength and endurance)

    Measured using an isokinetic dynamometer (Biodex) to assess peak torque and total work in 30 repetitions of knee flexion.

    Time frame: 6 months

  14. Thigh Muscle Volume

    Measured determined from contiguous axial fat-water separation 3T magnetic resonance images of both thighs

    Time frame: 6 months

  15. Biochemical markers of skeletal muscle protein content

    Measured via western blotting from a skeletal muscle biopsy of the vastus lateralis muscle. Proteins of interest include those found in mitochondria, contractile signaling pathways, insulin signaling pathways, and in glucose and fat metabolism.

    Time frame: 6 months

  16. Biochemical markers of skeletal muscle structure

    Measured via immunofluorescence from a skeletal muscle biopsy of the vastus lateralis muscle. Outcomes of interest include skeletal muscle capillarization, lipid content, and fiber type and cross sectional area.

    Time frame: 6 months

  17. Biochemical markers of skeletal muscle enzyme activity

    Measured via spectrophotometer to assess the maximal enzyme activity of enzymes involved in skeletal muscle oxidative capacity, from a biopsy of the vastus lateralis muscle.

    Time frame: 6 months

  18. Whole-body fat and fat-free mass

    Measured using a body composition device (BodPod) to estimate whole body fat (in kg and %) and fat free mass (in kg and %).

    Time frame: 6 months

  19. Visceral adipose tissue

    Volumes of adipose tissue in the visceral region measured using 3T fat-water separation magnetic resonance imaging

    Time frame: 6 months

  20. Liver fat fraction

    Measured as percent of liver volume composed of fat pixels determined from 3 slices through the middle of the liver using the PROFIT1 3T magnetic resonance images sequence.

    Time frame: 6 months

  21. Body circumferences

    Circumferences of the waist, hip and neck, measured using an inelastic tape

    Time frame: 6 months

  22. Concentration of inflammation biomarkers in blood

    Assessments from blood including leptin, adiponectin, Tumour Necrosis Factor alpha (TNF-a), Interleukin-6 (IL-6), C-reactive protein (CRP). These measures have been grouped together as the markers will be considered together when interpreted.

    Time frame: 6 months

  23. Lipid panel: high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total Cholesterol, Triglycerides

    Analyzed from blood serum using a clinical assay at a core lab.

    Time frame: 6 months

  24. Hemoglobin A1c

    Analyzed from blood plasma using a clinical assay at a core lab.

    Time frame: 6 months

  25. Dietary intake

    Various components of dietary intake including macronutrients and micronutrients will be assessed through 3-day food records over 2 weekdays and 1 weekend collected using Automated Self-Administered 24hour (ASA-24) online system.

    Time frame: 3 months, 6 months, 12 months

  26. Liver enzymes: alanine transaminase (ALT), aspartate aminotransferase (AST), and albumin

    Assessment of ALT, AST, and albumin via a fasting blood serum draw, analyzed on a clinical assay at a core lab.

    Time frame: 6 months

  27. Liver fibrosis

    Liver T1 time evaluated using the PROFIT1 magnetic resonance sequence, validated marker of liver fibrosis.

    Time frame: 6 months

  28. Aerobic physical activity adherence

    Average adherence to prescribed aerobic physical activity weekly minutes measured via Garmin smart watch

    Time frame: 6 months, 12 months

  29. Resistance exercise adherence

    Average adherence to prescribed resistance exercise activity weekly sessions via an attendance log

    Time frame: 6 months, 12 months

  30. Diet quality

    An overall measure of alignment with the dietary guidelines measured via the Canadian healthy eating index calculated from 3-day diet records

    Time frame: 3 months, 6 months, 12 months

  31. Health-related quality of life

    Assessed by RAND-36, where an independent score is provided for 8 scales ranging from 0 to 100 and 2 component summary scales ranging from 0-50 with a higher score indicating better quality of life.

    Time frame: 3 months, 6 months, 12 months

  32. Menopausal symptom presence and severity

    Assessed by the Menopause-specific Quality of Life (MENQOL) questionnaire. Each of four domains is constrained between 1 to 8 where a higher score indicates more symptoms.

    Time frame: 3 months, 6 months, 12 months

  33. Psychosocial stress

    Assessed by the perceived stress scale (PSS-14) where individual scores can range from 0 to 56 with higher scores indicating higher perceived stress

    Time frame: 3 months, 6 months, 12 months

  34. Depression & Anxiety

    Measured by the Hospital Anxiety and Depression Scale (HADS); score ranges from 0-21 for each of depression and anxiety with a higher score indicating more severe depression or anxiety

    Time frame: 3 months, 6 months, 12 months

  35. Barriers and self-efficacy for physical activity

    Assessed by the barriers to self-efficacy scale (BARSE). For each item, participants indicate their confidence to execute the behavior on a 100-point percentage scale comprised of 10-point increments, ranging from 0% (not at all confident) to 100% (highly confident). Total strength for each measure of self-efficacy is then calculated by summing the confidence ratings and dividing by the total number of items in the scale, resulting in a maximum possible efficacy score of 100.

    Time frame: 3 months, 6 months, 12 months

  36. Physical activity motivation

    Assessed via the multi-process action control approach, which is a series of questionnaires developed to understand affective attitudes, instrumental attitudes, perceived capability over physical activity, perceived opportunity for physical activity, decisional intentions, behavioural regulation, physical activity habits, and identity around physical activity. Higher scores represent better physical activity motivations. (Reference: Rhodes, R.E. (2017). The evolving understanding of physical activity behavior: A multi-process action control approach. In A. J. Elliot (Ed), Advances in Motivation Science. (pp. 171-205).)

    Time frame: 3 months, 6 months, 12 months

  37. Sleep quality - subjective

    Subjectively assessed by the Pittsburgh Sleep Quality Index (PQSI), which measures components of sleep: sleep duration, disturbance, sleep latency, daytime dysfunction due to sleepiness, sleep efficiency, overall sleep quality, and sleep medication use, with higher scores reflecting poorer sleep quality.

    Time frame: 3 months, 6 months, 12 months

  38. Sleep quantity and quality - device measured

    Measured via Garmin smart watch for the total sleep duration and efficiency.

    Time frame: 3 months, 6 months, 12 months

  39. Self-reported physical activity

    Assessed by the Recent Physical Activity Questionnaire (RPAQ) that collects information about types and amounts of activity (sedentary and physical activities) over the last 3 months in the following domains: leisure time, occupation, commuting, domestic life, with greater scores indicating longer time engaging in forms of activity.

    Time frame: 3 months, 6 months, 12 months

  40. Serum Estradiol

    Assessed using fasting blood serum in a clinical assay.

    Time frame: 6 months

  41. Salivary Estradiol

    Assessed using a salivary sample in-house using a clinical assay.

    Time frame: 6 months

  42. Hemoglobin

    Assessed using a fasting blood plasma sample in a clinical assay at a core lab.

    Time frame: 6 months

  43. Free fatty acids

    Assessed using fasting blood serum in a clinical assay.

    Time frame: 6 months

  44. Body weight

    Assessed using a calibrated scale attached to the BodPod body composition device.

    Time frame: 6 months

  45. Body mass index (BMI)

    Calculated from a measurement of height using a stadiometer and body weight (detailed above).

    Time frame: 6 months

  46. Energy Balance

    Energy balance will be quantified as: 3-day avg calorie intake - \[estimated resting metabolic rate + 3-day avg Garmin estimate of physical activity energy expenditure + 10% of calorie intake (thermic effect of food)\].

    Time frame: 3 months, 6 months, 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Aug 2027, 38 months after the start.

Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 38 months is above that.

Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 3, 2024
StartActual
May 3, 2024
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2028
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06345937
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Amy Kirkham (Assistant Professor, University of Toronto) — Principal investigator
First posted
Apr 3, 2024
Start date
May 3, 2024
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Sep 17, 2025

Study contacts

Amy A. Kirkham, PhD
Contact
amy.kirkham@utoronto.ca
416-946-4069
Jenna B. Gillen, PhD
Contact
jenna.gillen@utoronto.ca
416-978-3244
Amy A. Kirkham, PhD
principal investigator · University of Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion